Since the end of the 1990s, several major changes have occurred in the postsurgical management of differentiated thyroid cancers—for example, appreciation of the importance of thyroglobulin (Tg) assays in follow-up, a parallel appreciation of the relative insensitivity of follow-up 131I scans 9, and the concurrent development of recombinant humanized tsh (rhtsh). Here, TG is linked to thyroid gland carcinoma.